Online inquiry

IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ14157MR)

This product GTTS-WQ14157MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.

Specifications
Product type	mRNA
Modified bases	5-Methoxy-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_000565.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3570
UniProt ID	P08887

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14157MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ11432MR	IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	MEDI-8897
GTTS-WQ15008MR	IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	SJ25C1 scFv-28Z CAR
GTTS-WQ11259MR	IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	MEDI4736
GTTS-WQ3778MR	IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	BAY-1834942
GTTS-WQ60MR	IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	(131)I-chTNT-1/B
GTTS-WQ399MR	IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	2xCon4C
GTTS-WQ2546MR	IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	AMG 477
GTTS-WQ1698MR	IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	aDabi-Fab

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST